Working… Menu

Ovarian Cancer Treatment With a Liposome Formulated mRNA Vaccine in Combination With (Neo-)Adjuvant Chemotherapy (OLIVIA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04163094
Recruitment Status : Recruiting
First Posted : November 14, 2019
Last Update Posted : December 5, 2019
BioNTech RNA Pharmaceuticals GmbH
Information provided by (Responsible Party):
Hans W. Nijman, MD PHD, University Medical Center Groningen

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : February 2023
Estimated Study Completion Date : December 2023